Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KQB198 |
| Synonyms | |
| Therapy Description |
KQB198 inhibits SOS1, potentially leading to decreased downstream KRAS signaling and reduced growth of tumor cells expressing KRAS (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KQB198 | KQB-198|KQB 198 | SOS1 Inhibitor 17 | KQB198 inhibits SOS1, potentially leading to decreased downstream KRAS signaling and reduced growth of tumor cells expressing KRAS (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06645886 | Phase I | Dasatinib + KQB198 KQB198 | A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies | Recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT06507306 | Phase I | KQB198 + Osimertinib KQB198 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Recruiting | USA | ITA | FRA | ESP | 2 |